Current Pipeline

We develop and sustain a robust portfolio of valuable products that address the unmet medical needs of patients.

We develop multifunctional antibody derivatives applicable in various fields such as immune-oncology and infectious diseases. Baiya Phytopharm currently employs a Plug ‘n’ Play strategy across three of its research and development (R&D) initiatives: PlantamAb™ (Ab derived from plant), Fuseplanta™ (Ab fusion proteins), and Multiplanta™ (multispecific Ab). This strategy involves the generation of novel drug molecules targeting diverse disease mechanisms. 

Beyond antibodies, Baiya Phytopharm has developed PhytoPacked™, a plant-derived VLP-based mRNA delivery platform designed to enable efficient intracellular delivery of customer-defined mRNA payloads for vaccines and gene therapy applications.

Baiya's Pipeline
We develop multifunctional antibody derivatives applicable in various fields such as immune-oncology and infectious diseases. Baiya Phytopharm currently employs a Plug 'n' Play strategy across three of its research and development (R&D) initiatives: PlantamAb™ (Ab derived from plant), Fuseplanta™ (Ab fusion proteins), and Multiplanta™ (multispecific Ab). This strategy involves the generation of novel drug molecules targeting diverse disease mechanisms.
Pipeline Technology Molecule Code Target Indication Discovery Preclinical IND Sub. Phase 1
Oncology
 Fuseplanta™ BFP-B3T-001 PD1, BBB receptor Brain metastases
PlantamAb™ BPM-CA-001 PD1 TBD
Fuseplanta™ BFP-ICK-001 PD1, IL-15 TBD
Non-Oncology
 PlantamAb™ BPM-RSV-001 F protein RSV infection
PlantamAb™ BPM-RSV-002 F protein RSV infection
PlantamAb™ BPM-PD-001 IgE Asthma
VLP-mRNA
Delivery
Platform
 PhytoPacked™ Vaccines mRNA (HA, RBD) Rapid-response respiratory vaccines
PhytoPacked™ Gene Therapy mRNA (cell-targeted delivery) Precision mRNA therapeutics
Current Pipeline